The trajectory of Sildenafil presents a complex picture for investors. While the initial launch generated massive returns, the end of its intellectual property protection opened the floodgates to off-brand alternatives, dramatically reducing market share. This poses a specific risk for firms relying on similar blockbuster products, suggesting that

The story of Viagra, and its developer copyright, presents a challenging case study for investors. At first a blockbuster drug, generating billions in sales , its patent expiration created a flood of generic competition , significantly impacting its market share . While some businesses may try to capitalize on male sexual dysfunction, the existing